213 related articles for article (PubMed ID: 6801211)
1. Effects of aldose reductase inhibitor treatment in diabetic polyneuropathy - a clinical and neurophysiological study.
Fagius J; Jameson S
J Neurol Neurosurg Psychiatry; 1981 Nov; 44(11):991-1001. PubMed ID: 6801211
[TBL] [Abstract][Full Text] [Related]
2. Clinical trial of an aldose reductase inhibitor in diabetic neuropathy.
Handelsman DJ; Turtle JR
Diabetes; 1981 Jun; 30(6):459-64. PubMed ID: 6785131
[TBL] [Abstract][Full Text] [Related]
3. Clinical and neurophysiological studies with the aldose reductase inhibitor, sorbinil, in symptomatic diabetic neuropathy.
Lewin IG; O'Brien IA; Morgan MH; Corrall RJ
Diabetologia; 1984 Jun; 26(6):445-8. PubMed ID: 6432615
[TBL] [Abstract][Full Text] [Related]
4. Aldose reductase inhibition: studies with alrestatin.
Gabbay KH; Spack N; Loo S; Hirsch HJ; Ackil AA
Metabolism; 1979 Apr; 28(4 Suppl 1):471-6. PubMed ID: 122298
[TBL] [Abstract][Full Text] [Related]
5. Effect of an aldose reductase inhibitor on diabetic peripheral neuropathy. Preliminary report.
Culebras A; Alió J; Herrera JL; López-Fraile MI
Arch Neurol; 1981 Feb; 38(2):133-4. PubMed ID: 6781454
[No Abstract] [Full Text] [Related]
6. Limited benefit of treatment of diabetic polyneuropathy with an aldose reductase inhibitor: a 24-week controlled trial.
Fagius J; Brattberg A; Jameson S; Berne C
Diabetologia; 1985 Jun; 28(6):323-9. PubMed ID: 3930330
[TBL] [Abstract][Full Text] [Related]
7. Effects of sorbinil therapy in diabetic patients with painful peripheral neuropathy and autonomic neuropathy.
Jaspan JB; Herold K; Bartkus C
Am J Med; 1985 Nov; 79(5A):24-37. PubMed ID: 3000176
[TBL] [Abstract][Full Text] [Related]
8. Clinical studies with an aldose reductase inhibitor in the autonomic and somatic neuropathies of diabetes.
Jaspan JB; Towle VL; Maselli R; Herold K
Metabolism; 1986 Apr; 35(4 Suppl 1):83-92. PubMed ID: 3083212
[TBL] [Abstract][Full Text] [Related]
9. Six-month treatment with sorbinil in asymptomatic diabetic neuropathy. Failure to improve abnormal nerve function.
Martyn CN; Reid W; Young RJ; Ewing DJ; Clarke BF
Diabetes; 1987 Sep; 36(9):987-90. PubMed ID: 3111914
[TBL] [Abstract][Full Text] [Related]
10. Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil.
Sima AA; Bril V; Nathaniel V; McEwen TA; Brown MB; Lattimer SA; Greene DA
N Engl J Med; 1988 Sep; 319(9):548-55. PubMed ID: 3136331
[TBL] [Abstract][Full Text] [Related]
11. Treatment of severely painful diabetic neuropathy with an aldose reductase inhibitor: relief of pain and improved somatic and autonomic nerve function.
Jaspan J; Maselli R; Herold K; Bartkus C
Lancet; 1983 Oct; 2(8353):758-62. PubMed ID: 6137601
[TBL] [Abstract][Full Text] [Related]
12. The effect of an aldose reductase inhibitor (Sorbinil) on diabetic neuropathy and neural function of the retina: a double-blind study.
Christensen JE; Varnek L; Gregersen G
Acta Neurol Scand; 1985 Feb; 71(2):164-7. PubMed ID: 3920861
[TBL] [Abstract][Full Text] [Related]
13. [Diabetic neuropathy: treatment trial with an aldose reductase inhibitor (Sorbinil)].
Christensen JE; Larsen AB; Gregersen G
Ugeskr Laeger; 1987 Nov; 149(46):3111-4. PubMed ID: 3127975
[No Abstract] [Full Text] [Related]
14. Aldose reductase inhibition in diabetic neuropathy: clinical and neurophysiological studies of one year's treatment with sorbinil.
O'Hare JP; Morgan MH; Alden P; Chissel S; O'Brien IA; Corrall RJ
Diabet Med; 1988 Sep; 5(6):537-42. PubMed ID: 2974776
[TBL] [Abstract][Full Text] [Related]
15. Prolonged aldose reductase inhibition in chronic peripheral diabetic neuropathy: effects on microangiopathy.
Jennings PE; Nightingale S; Le Guen C; Lawson N; Williamson JR; Hoffman P; Barnett AH
Diabet Med; 1990 Jan; 7(1):63-8. PubMed ID: 2137066
[TBL] [Abstract][Full Text] [Related]
16. Can aldose reductase inhibition ameliorate diabetic neuropathy?
González ER
JAMA; 1981 Sep; 246(11):1169-70. PubMed ID: 6790734
[No Abstract] [Full Text] [Related]
17. Autonomic and peripheral nerve function in early diabetic neuropathy. Possible influence of a novel aldose reductase inhibitor on autonomic function.
Sundkvist G; Lilja B; Rosén I; Agardh CD
Acta Med Scand; 1987; 221(5):445-53. PubMed ID: 3111179
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological inhibition of aldose reductase in human diabetic neuropathy.
Jaspan J
Drugs; 1986; 32 Suppl 2():23-9. PubMed ID: 2431859
[TBL] [Abstract][Full Text] [Related]
19. Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. The Tolrestat Study Group.
Sima AA; Greene DA; Brown MB; Hohman TC; Hicks D; Graepel GJ; Bochenek WJ; Beg M; Gonen B
J Diabetes Complications; 1993; 7(3):157-69. PubMed ID: 8343610
[TBL] [Abstract][Full Text] [Related]
20. [Effects of the aldose reductase inhibitor on diabetic polyneuropathy--the efficacy of F wave measurement].
Shimada H; Miki T; Kyogoku I; Kawagishi T; Inaba M; Okuno Y; Nishizawa Y; Morii H
No To Shinkei; 1998 Sep; 50(9):817-20. PubMed ID: 9789304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
